Endocrine-Related Cancer

Article	Citations
Defining aging-associated factors that increase susceptibility to prostate cancer	118
Survival following resection of 10,244 lung neuroendocrine tumours: a population study	74
The diagnostic value of 68Ga-pentixafor PET/CT in differentiating adrenal aldosterone-producing adenomas from non-functional adenomas	68
Metastatic neuroendocrine neoplasms of the breast: a systematic review	60
Radiation reprograms fibroblasts to drive prostate cancer therapy resistance	57
ERRATUM: Roles of the HOXA10 gene during castrate-resistant prostate cancer progression	46
Acknowledgement to reviewers	41
Refining long-term surveillance requirements in patients with differentiated thyroid cancer	35
Chemokines with CXC motif and their receptors in neuroendocrine neoplasms	34
Prognostic of recurrence and survival in poorly differentiated thyroid cancer	32
Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications	31
Targeting growth hormone in cancer: future perspectives	30
Сytotoxic T lymphocyte-associated protein 4 (CTLA4) is overexpressed in a subset of prolactin- and growth hormone-secreting pituitary adenomas	29
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs	26
Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing	25
NP-101 in combination with nivolumab and ipilimumab in metastatic extrapulmonary neuroendocrine carcinomas (EP-NECs): A pilot study	24
Clinical presentation of bone metastases in neuroendocrine tumors: a retrospective cohort study	24
FROM DISCOVERY SCIENCE TO THE CLINIC - HERITABLE ENDOCRINE CANCERS AND RELATED DISORDERS: Functional imaging in hereditary endocrine neoplasms: evolving modalities and clinical implications	23
Update on the genetics of paragangliomas	23
Interleukin-6 promotes the dedifferentiation of papillary thyroid cancer cells	23
Genistein induces endocrine resistance in human breast cancer by suppressing H3K27 trimethylation	22
Lymphangioleiomyomatosis: where endocrinology, immunology and tumor biology meet	22
MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells	22
Impact of sex hormones on development and progression in NEN: a new therapeutic target?	21
CORRIGENDUM: GPER1 is regulated by insulin in cancer cells and cancer-associated fibroblasts	21

Peptide receptor radionuclide therapy in malignant insulinoma	20
The genetic changes in 11p15.5-related pheochromocytomas and paragangliomas	18
Metabolically active brown adipose tissue in PPGL: an observational cohort study	17
Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells	17
FAM64A contributes to ovarian cancer proliferation and metastasis by suppressing TWIST1 ubiquitination and degradation	17
B7-H3 (CD276) as a candidate therapeutic target in medullary thyroid cancer	16
CCL2 expression predicts clinical outcomes and regulates E-cadherin and angiogenesis in pituitary tumours	15
Lamin B1: a novel biomarker in adult and pediatric adrenocortical carcinoma	15
PRRT for well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs)	15
Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid in Australia	15
lncRNA DIRC3 regulates invasiveness and insulin-like growth factor signaling in thyroid cancer cells	15
Determinants of false-positive plasma free metanephrines and methoxytyramine: the role of medications and chronic disease	15
Defining the ATA-2025 ‘consider RAIT’ zone in older patients with N1b PTC	15
Nonmalignant AR-positive prostate epithelial cells and cancer cells respond differently to androgen	14
Gender-affirming care and endocrine-related cancers	14
Distortion in transmission of pathogenic SDHB- and SDHD-mutated alleles from parent to offspring	14
Bone metastasis in endocrine-related cancer: unravelling invasion and destruction	14
Whole-exome sequencing of rectal neuroendocrine tumors	14
RET signalling in the pituitary: a double-edged sword for differentiation, apoptosis and therapeutic strategies in acromegaly	13
Steroid profile in patients with breast cancer and in mice treated with mifepristone	13
ThyroidPrint®: clinical utility for indeterminate thyroid cytology	13
Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective	13
The role of the B7 family in autoimmune thyroid diseases and thyroid cancer	13
Alternative schedule of temozolomide/capecitabine in neuroendocrine neoplasms	13
Artificial intelligence in pheochromocytoma and paraganglioma: from diagnostic modeling to clinically integrated decision support systems	13
Protective TGFβ2/SMAD3 Axis Identified by TWAS in Papillary Thyroid Cancer	13
Immunotherapy for endocrine tumours: a clinician’s perspective	13
Embryonic stem cell factor FOXD3 (Genesis) defects in gastrointestinal stromal tumors	13
From bench to bedside in the sella: translational developments in pituitary tumour genetics	12
Elevated vasoactive intestinal peptide concentrations poorly predict VIPoma	12
Genetic variants of glucose metabolism and exposure to smoking in African American breast cancer	12
Ciliogenesis in pancreatic neuroendocrine tumors: insight into the role of WDR60	12
Exploring the tumor suppressor role of RIN1 in familial thyroid carcinoma	12
Genome-wide association studies in advanced prostate cancer: KYUCOG-1401-A study	12
Clinical features of plurihormonal pituitary adenoma subtypes	12
Single-Cell and Spatial Transcriptomics Define a Progenitor Subpopulation and Fibroinflammatory Niche at the Leading Edge of Parathyroid Carcinoma	12
The role of the tumor microenvironment in papillary thyroid microcarcinoma nodal metastasis	12
Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA	12
Acknowledgement to reviewers	11
Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma	11
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer	11
Acknowledgement to reviewers	11
In vivo and in vitro analysis of functional effects of the SDHD H50R variant	11
Relationship between vascular density and microenvironment in medullary thyroid carcinoma	11
Subgroup analysis of steadily increased trends in medullary thyroid carcinoma incidence and mortality in the USA, 2000–2020: a population-based retrospective cohort study	11
Ampullary composite gangliocytoma/neuroma and neuroendocrine tumor management	11
NANETS Guidelines for the diagnosis and management of stage I–III rectal neuroendocrine tumors	10
Genetic disorders and insulinoma/glucagonoma	10
Diagnosis and management of parathyroid carcinoma: a state-of-the-art review	10
Reactivated thyroid hormone receptor β attenuates anaplastic thyroid cancer (ATC) stem cell activity	10

The role of stem cells in pituitary tumour formation	10
Mammary gland development and EDC-driven cancer susceptibility in mesenchymal ERα-knockout mice	10
Systems biology successes and areas for opportunity in prostate cancer	10
ERRATUM: Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2	10
Cancer in Ecuadorian subjects with Laron syndrome (ELS)	10
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland	10
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC	10
Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort	9
COL12A1 as a prognostic biomarker links immunotherapy response in breast cancer	9
Establishment of patient-derived xenografts for neuroendocrine tumors in the avian embryo model	9
Spectrum and carcinogenic properties of thyroglobulin gene fusions in thyroid	9
Deiodinases in thyroid tumorigenesis	9
Non-pituitary GH regulation of the tissue microenvironment	9
Molecular imaging and radioligand therapies in pheochromocytomas and paragangliomas	9
Beyond the three P’s: adrenal involvement in MEN1	9
Sexual dimorphism in thyroid cancer: evidence from preclinical studies	9
Targeting anti-apoptosis as a therapeutic strategy in neuroendocrine neoplasms	8
International symposium on pheochromocytoma: an event of dedicated healthcare professionals and researchers striving for better patient outcomes	8
Chemoembolization using streptozotocin versus embolization in metastatic NETs	8
Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center	8
Surrogate molecular classification of LAR breast cancer in routine workflow	8
In memoriam: Charis Eng MD PhD (1962–2024)	8
Developing an epithelial signature for prognosis of papillary thyroid carcinoma	8
Genetic variants and down-regulation of CACNA1H in pheochromocytoma	8
Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane	8
Management of high-grade neuroendocrine neoplasms: impact of functional imaging	8
Promoter mutation-independent TERT expression is related to the immune-enriched milieu in papillary thyroid cancer	8
Cutoff value of thyroglobulin in needle aspirates for screening neck masses of thyroid carcinoma	8
MicroRNAs as regulators of tumor metabolism	8
The World Health Organization classifications of pituitary neuroendocrine tumours: a clinico-pathological appraisal	8
miR-3156-5p is downregulated in serum of MEN1 patients and regulates expression of MORF4L2	8
The science behind the relations among cancer, height, growth patterns, and growth hormone axis	8
Rethinking paraganglioma management: distinct clinical pathways for head and neck versus other sites	8
Genotype-specific development of MEN 2 constituent components in 683 RET carriers	8
Long-term calcitonin after thyroidectomy for medullary thyroid cancer in MEN2A	8
Limited value of genetic profiling in guiding radioiodine therapy for metastatic differentiated thyroid cancer	8
Precocious puberty due to intracranial germ cell tumors: a case–control study	7
The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading	7
Cryoablation of bone metastases in thyroid and adrenocortical cancers	7
Acknowledgement to reviewers	7
Mitochondrial dynamics and oxidative phosphorylation as critical targets in cancer	7
SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma	7
GLP1 receptor agonism alters growth and therapeutic response in prostate cancer	7
A clinically applicable molecular classification of oncocytic cell thyroid nodules	7
Tumor suppressor gene ARMC5 controls adrenal redox state through NRF1 turnover	7
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms	7
Characterization of small intestinal neuroendocrine tumorlets	7
The secreted protein SPARCL1 suppresses tumor progression in papillary thyroid carcinoma via SLC3A2-mediated ferroptosis	7
Unregulated LDL cholesterol uptake is detrimental to breast cancer cells	6
Predictors of cancer in patients with endogenous Cushing’s syndrome	6
Lipid synthesis seems to drive proliferation in Men1 mouse adrenals and human adrenocortical cell lines	6
Ageing and pituitary neuroendocrine tumours (PitNETs): from bench to bedside	6
Exploring chromosomal instability and clonal heterogeneity in breast cancer	6
DNA methylation is a comprehensive marker for pediatric adrenocortical tumors	6
Reciprocal cancer risks between thyroid and breast cancer: a systematic review and meta-analysis	6
Inflammation-based score in pediatric adrenocortical carcinoma	6
Sig27 stratifies prostate cancer recurrence by assessing the immunosuppressive properties of tumors	6
Management of advanced high grade gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): comprehensive review of the current literature	6
Insulinomatosis: new aspects	6
Adjuvant and neoadjuvant therapy with cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: a systematic revie	6
Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer	6
Endocrine cancer trends 1990–2021: global disparities and health inequalities	6
Role of GDH and PARP inhibitors as novel treatments for SDHB-deficient PPGLs	6
Adrenal tumors in the elderly	6
The prevalence and clinical significance of 68Ga-DOTANOC incidentaloma	6
MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells	6
Risk of complications after core needle biopsy in pheochromocytoma/paraganglioma	6
Pathological features in non-neoplastic congenital and adult hyperinsulinism: from nesidioblastosis to current terminology and understanding	5
Insulin-like growth factor-1 receptor crosstalk with integrins, cadherins, and the tumor microenvironment: sticking points in understanding IGF1R function in cancer	5
Association of DNA methylation with steroidogenic enzymes in Cushing’s adenoma	5
Long non-coding RNA MFSD4A-AS1 promotes lymphangiogenesis and lymphatic metastasis of papillary thyroid cancer	5
Pituitary tumor-transforming gene 1 and endocrine cancers: an up-to-date review through history, current insights and future perspectives	5
Real-world effectiveness of darolutamide in metastatic castration-resistant prostate cancer	5
TLR4 inhibition suppresses growth in oestrogen-induced prolactinoma models	5
Autophagic blockade potentiates anlotinib-mediated ferroptosis in anaplastic thyroid cancer	5
Multimodal treatment for resectable neuroendocrine carcinoma of the cervix	5
Multivariable model versus AJCC staging system: cancer-specific survival predictions in adrenocortical carcinoma	5
Hallmarks of disease: how tuned hierarchies of intelligent molecular neural networks (MNNs) may matter	5
HMGCS1 as a potential mediator of resistance to EZH2 inhibition via ferroptosis mediated by PI3K/AKT/mTOR pathway in the pancreatic neuroendocrine neoplasms	5
Second-line treatment and prognostic factors in neuroendocrine carcinoma: the RBNEC study	5

Clinicopathological features and outcomes of thyroid nodules with EIF1AX mutations	5
Patient-reported burden associated with pheochromocytoma/paraganglioma diagnosis	5
Expanding horizons in Endocrine-Related Cancer : innovation, imagination, and a shared global vision	5
Mobile elements in pituitary neuroendocrine tumors: integrative evidence and future directions	5
ERRATUM: The role of oestrogen receptor α in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2	5
Comprehensive analysis of germline and somatic SDHA alterations reveals rare incidental germline variants and prognostic implications of somatic loss in	4
Discordant risk factors between pancreatic neuroendocrine neoplasms and pancreatic ductal adenocarcinoma	4
Impact of sex on treatment decisions and outcome in patients with neuroendocrine neoplasms	4
Why do we continue to have an incomplete understanding of estrogen receptor(s) actions in cancer systems?	4
Therapy-related myeloid neoplasms in 177Lu-DOTATATE treated neuroendocrine tumor patients: how great is the risk?	4
Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas	4
Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study	4
The aggressiveness of succinate dehydrogenase subunit B-deficient chromaffin cells is reduced when their bioelectrical properties are restored by glibenclamide	4
Predictive model for the diagnosis of ectopic Cushing syndrome	4
Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms	4
Phenotype of pheochromocytoma and paraganglioma by germline mutation: a Korean multicenter study	4
Netrin–DCC inhibition suppresses neuroendocrine neoplasm growth in vivo	4
Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data	4
Intraprostatic steroid hormones and endocrine disruptors in prostate cancer	4
Improved and individualized approach to adrenal surgery	4
Lineage-specific steroidomic signatures in pituitary neuroendocrine tumors: pregnenolone enrichment in SF-1 lineage and associations with tumor behavior	4
Association between pembrolizumab-related thyroid adverse events and outcomes in early-stage triple-negative breast cancer patients	4
Regulation of epinephrine biosynthesis in HRAS-mutant paragangliomas	4
Development and validation of long-acting recombinant human TSH using SAFA technology	4
Molecular determinants of AR–enhancer interaction and cistrome reprogramming in prostate cancer progression	4
Congenital IGF-1 deficiency protects from cancer: lessons from Laron syndrome	4
ERRATUM: Mutational landscape of non-functional adrenocortical adenomas	4
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study	4
Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN	4
Mannose enhances anti-tumor effect of PLX4032 in anaplastic thyroid cancer	3
Heme-oxygenase-1: a key player in thyroid carcinoma development	3
Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells	3
AGO2 protein: a key enzyme in the miRNA pathway as a novel biomarker in adrenocortical carcinoma	3
NIFTPs may be reclassified not only from FVPTCs but also from follicular adenomas	3
Functional analysis of AIP variants in a cohort of neuroendocrine neoplasms	3
Hormone secretion predicts poor prognosis in lung neuroendocrine neoplasms	3
Growth hormone and radiation therapy: friend, foe, or both?	3
Breast cancer metastasis in obesity: extracellular vesicles as drivers	3
Clinicopathological characteristics associated with the prognosis of recurrent gonadotroph tumors	3
Friend or foe? Deciphering androgen receptor action to improve bipolar androgen therapy for prostate cancer	3
Core needle biopsy in pheochromocytoma/paraganglioma: should it be considered?	3
An update on genetically engineered mouse models of pancreatic neuroendocrine neoplasms	3
Therapeutic inhibition of ATR in differentiated thyroid cancer	3
Second primary cancers and survival among neuroendocrine tumor patients	3
Mechanisms of resistance to RET-directed therapies	3
Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy	3
Reappraisal of BRAFK601E-positive thyroid tumors in the NIFTP era	3
FT3 and FT3/FT4 ratio are decreased and not compensated by levothyroxine treatment in TKI-treated thyroid cancer patients	3
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors	3
Orlistat combined with everolimus suppresses pancreatic neuroendocrine tumor progression via inhibiting PI3K/AKT/mTOR signaling mediated by SLFN5	3
Impact of presurgical beta-blockade on surgical outcomes in patients with PPGLs	3
Autocrine/paracrine growth hormone in cancer progression	3
Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells	3
Nuclear and mitochondrial DNA alterations in pheochromocytomas and paragangliomas, and their potential treatment	3
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care	3
Clinical and prognostic significance of parathyroid hormone-related protein in breast cancer: a systematic review and meta-analyses of observational studies in women	3
Efficacy and safety of pralsetinib in Chinese advanced RET-mutant medullary thyroid cancer patients	3
Prognostic value of the Weiss and Wieneke (AFIP) scoring systems in pediatric ACC – a mini review	3
The immune cell infiltrate in the tumour microenvironment of phaeochromocytomas and paragangliomas	3
Proteomic signatures of adipocyte recruitment in breast cancer	3